Severe Thiopurine‐Induced Myelosuppression in a Pediatric Acute Lymphoblastic Leukemia Patient With the NUDT15 *1/*6 Genotype: A Brief Report
Clinical and Translational Science · 2026-06 · 19 (6)
DOI: 10.1111/cts.70639 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical and Translational Science, online erschienen am 12.06.2026. Verfasst von Jillian Fry und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology/Oncology/BMT, Children's Mercy Kansas City, Kansas City, USA. Hauptthemen laut MEDLINE: Antimetabolites, Antineoplastic, Mercaptopurine, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Variants in TPMT and NUDT15 genes that affect thiopurine metabolism can guide personalized dosing to minimize toxicity. Decreased or no appreciable NUDT15 activity demonstrates impaired breakdown of active thiopurine metabolites which can lead to severe adverse events including potentially life‐threatening myelosuppression. Recently, the NUDT15*6 allele was re‐classified from having uncertain function to no function by the Clinical Pharmacogenetics Implementation Consortium. Here, we present a pediatric patient with a NUDT15*1/*6 genotype who experienced significant thiopurine‐induced myelosuppression. The patient is a 4‐year‐old female with standard risk‐average precursor B‐cell acute lymphoblastic leukemia treated per AALL1731. Exome sequencing determined TPMT*1/*1 (normal metabolizer) and NUDT15*1/*6 (indeterminate metabolizer). After 75 mg/m 2 /day mercaptopurine, myelosuppression necessitated a three‐week delay prior to the next phase of therapy. With 60 mg/m 2 /day thioguanine in a subsequent phase of therapy, she was admitted twice for fever and neutropenia. In the final phase of therapy, mercaptopurine at standard dosing of 75 mg/m 2 /day caused severe neutropenia and thrombocytopenia with elevated metabolite levels that required stopping mercaptopurine. After neutrophil recovery, a trial of 50% standard dosing was not tolerated and her dose was reduced to 27%, which was tolerated. Among 339 patients with cancer, sequencing revealed an allele frequency of 0.88% for NUDT15*6 . In a larger cohort sequenced for suspicion of rare genetic disease, the frequency of NUDT15*6 was 0.15% among 1011 unrelated individuals. This brief report supports the recent update that patients with the NUDT15*1/*6 genotype should be classified as intermediate metabolizers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology/Oncology/BMT, Children's Mercy Kansas City, Kansas City, USA.
- Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy Research Institute, Kansas City, USA.
- Department of Pathology and Laboratory Medicine, Children's Mercy Kansas City, Kansas City, USA.
- Division of Laboratory Genetics and Genomics, Children's Mercy Kansas City, Kansas City, USA.
- School of Medicine, University of Missouri, Kansas City, USA.
ORCID-Profile: Erin C Boone, Wendy Y Wang, Shobana John, Andrea Gaedigk, Laura B Ramsey
Zitieren
APA
Fry, J., Boone, E. C., Wang, W. Y., John, S., Lansdon, L. A., Farooqi, M. S., Yoo, B., Gaedigk, A., August, K., Flatt, T. G., & Ramsey, L. B. (2026). Severe Thiopurine‐Induced Myelosuppression in a Pediatric Acute Lymphoblastic Leukemia Patient With the NUDT15 *1/*6 Genotype: A Brief Report. Clinical and Translational Science, 19(6). https://doi.org/10.1111/cts.70639
Vancouver
Fry J, Boone EC, Wang WY, John S, Lansdon LA, Farooqi MS, et al. Severe Thiopurine‐Induced Myelosuppression in a Pediatric Acute Lymphoblastic Leukemia Patient With the NUDT15 *1/*6 Genotype: A Brief Report. Clinical and Translational Science. 2026;19(6). doi:10.1111/cts.70639
BibTeX
@article{Fry2026,
author = {Fry, Jillian and Boone, Erin C and Wang, Wendy Y and John, Shobana and Lansdon, Lisa A and Farooqi, Midhat S and Yoo, Byunggil and Gaedigk, Andrea and August, Keith and Flatt, Terrie G and Ramsey, Laura B},
title = {Severe Thiopurine‐Induced Myelosuppression in a Pediatric Acute Lymphoblastic Leukemia Patient With the NUDT15 *1/*6 Genotype: A Brief Report},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {6},
doi = {10.1111/cts.70639}
}
EUVIMED